Page last updated: 2024-10-23

benserazide and Inadequate Sleep

benserazide has been researched along with Inadequate Sleep in 1 studies

Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belaid, H1
Adrien, J1
Laffrat, E1
Tandé, D1
Karachi, C1
Grabli, D1
Arnulf, I1
Clark, SD1
Drouot, X1
Hirsch, EC1
François, C1

Other Studies

1 other study available for benserazide and Inadequate Sleep

ArticleYear
Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Jul-02, Volume: 34, Issue:27

    Topics: Animals; Benserazide; Cholinergic Neurons; Diphtheria Toxin; Drug Combinations; Levodopa; Macaca fas

2014